BioSyntech Announces Increase to Bought Deal



    /THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT
    INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
    DISSEMINATION IN THE UNITED STATES./

    LAVAL, QC, June 20 /CNW/ - BioSyntech, Inc. (the "Corporation") (TSX:BSY)
is pleased to announce that the Corporation has reached an agreement with the
underwriters to increase the size of its bought deal announced on June 16,
2008. The syndicate, led by Dundee Securities Corporation, and including
Macquarie Capital Markets Canada Ltd., Versant Partners Inc. and Laurentian
Bank Securities Inc. have agreed to purchase an aggregate of 11,000 Units,
each comprised of $1,000 principal amount of subordinated secured convertible
debentures and 2,500 warrants, representing aggregate gross proceeds of
$11,000,000 to the Corporation. The Corporation has also granted to the
underwriters an over-allotment option, exercisable from time to time in the 60
days following closing of the offering, to purchase up to an additional 1,650
Units to cover over-allotments, for additional gross proceeds of up to
$1,650,000.
    The 12.00% subordinated secured convertible debentures (the "Debentures")
mature on December 31, 2009 and are convertible into common shares at any time
prior to maturity at a conversion price of $0.20 per share (the "Conversion
Price"). For every share issuable on conversion of the Debentures, the holder
will receive 1/2 of a common share purchase warrant (the "Warrants"), being
2,500 Warrants per $1,000 principal amount of Debentures. Each whole Warrant
is exercisable for a period of 5 years from the closing of the offering at a
purchase price of $0.22 per share.
    The offering is expected to close on or about July 4, 2008 and is subject
to certain conditions, including the receipt of the acceptance of the Toronto
Stock Exchange and any other required regulatory approvals.

    THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES
ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES
ABSENT REGISTRATION OR AN APPLICABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS. THIS PRESS RELEASE SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY THE SECURITIES, NOR SHALL THERE BE ANY SALE OF
THE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE
UNLAWFUL.

    FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions. There is no guarantee that the proposed
financing will be completed and that the Company will be in a position to meet
its obligations as they become due.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at www.sedar.com. These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.





For further information:

For further information: BioSyntech, Inc., Yvonne Kramer Ph.D., Sr.
Director Corporate & Business Development, (450) 686-2437, ext. 315, Email:
Yvonne.Kramer@biosyntech.com; or The Equicom Group, Arianna Vanin, Investor
Relations, (514) 844-4680, Email: avanin@equicomgroup.com

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890